source
- Biohaven's ataxia drug resubmission accepted by FDA, shares surge 36%Biohaven’s experimental drug troriluzole, being developed for spinocerebellar ataxia, was previously rejected by the FDA because the agency questioned the design of the registrational trial. The co…
- Roche reaffirms sales outlook despite weaker Xolair sales and looming generic competitionRoche reported third-quarter group sales of 16.1 billion Swiss francs, about $19.6 billion, a 7% increase that beat analysts' consensus estimate of 15.8 billion francs. The beat was helped by a ne…